These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 14690879)

  • 21. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
    Fishman M
    Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does naltrexone affect craving in abstinent opioid-dependent patients?
    Dijkstra BA; De Jong CA; Bluschke SM; Krabbe PF; van der Staak CP
    Addict Biol; 2007 Jun; 12(2):176-82. PubMed ID: 17508990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
    Bell J; Mutch C
    Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of psychiatric comorbidity on treatment outcome in patients undergoing diamorphine or methadone maintenance treatment.
    Schäfer I; Eiroa-Orosa FJ; Verthein U; Dilg C; Haasen C; Reimer J
    Psychopathology; 2010; 43(2):88-95. PubMed ID: 20068379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.
    Hulse GK; Ngo HT; Tait RJ
    Biol Psychiatry; 2010 Aug; 68(3):296-302. PubMed ID: 20537615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of very low-dose naltrexone during opiate detoxification.
    Mannelli P; Gottheil E; Buonanno A; De Risio S
    J Addict Dis; 2003; 22(2):63-70. PubMed ID: 12703669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.
    Maremmani I; Pani PP; Pacini M; Perugi G
    J Subst Abuse Treat; 2007 Jul; 33(1):91-8. PubMed ID: 17588494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injectable extended-release naltrexone for opioid dependence.
    Woody GE; Metzger DS
    Lancet; 2011 Aug; 378(9792):664-5; author reply 666. PubMed ID: 21856476
    [No Abstract]   [Full Text] [Related]  

  • 31. Favorable mortality profile of naltrexone implants for opiate addiction.
    Reece AS
    J Addict Dis; 2010 Jan; 29(1):30-50. PubMed ID: 20390697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naltrexone: a clinical perspective.
    Greenstein RA; Arndt IC; McLellan AT; O'Brien CP; Evans B
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):25-8. PubMed ID: 6469933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concerns about injectable naltrexone for opioid dependence.
    Wolfe D; Carrieri MP; Dasgupta N; Wodak A; Newman R; Bruce RD
    Lancet; 2011 Apr; 377(9776):1468-70. PubMed ID: 21529930
    [No Abstract]   [Full Text] [Related]  

  • 35. Response to Degenhardt et al.: 'depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy'.
    Brewer C
    Drug Alcohol Rev; 2008 Jul; 27(4):447-8; author reply 448-9. PubMed ID: 18584398
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy.
    Eder H; Jagsch R; Kraigher D; Primorac A; Ebner N; Fischer G
    Addiction; 2005 Aug; 100(8):1101-9. PubMed ID: 16042640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
    Tait RJ; Ngo HT; Hulse GK
    J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Naltrexone implants compared to methadone: outcomes six months after prison release.
    Lobmaier PP; Kunøe N; Gossop M; Katevoll T; Waal H
    Eur Addict Res; 2010; 16(3):139-45. PubMed ID: 20424458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
    Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
    Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review.
    Johansson BA; Berglund M; Lindgren A
    Addiction; 2006 Apr; 101(4):491-503. PubMed ID: 16548929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.